Skip to content

Study · Non-randomized trial · n = 33 · 1989

2 results

[A phase III trial comparing the antiemetic activity of tetracosactide with dexamethasone in combination with metoclopramide, diphenhydramine and clorazepate during chemotherapy including cisplatin].

Culine S, Azab M, Pietri F, Ghosn M, Ben Amor B, Lupera H, Theodore C, Renaux J, Droz JP

Bulletin du cancer1 Jan 1989

PMID2673437 (opens in a new tab)PepBankPUB-02673437
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In cisplatin chemotherapy patients, tetracosactide and dexamethasone with shared background antiemetics did not differ significantly in efficacy.

    In plain wordsIn cisplatin chemotherapy patients, tetracosactide and dexamethasone with the same background drugs did not differ significantly in efficacy.

    Peptide
    Cosyntropin
    Outcome
    No significant changeAntiemetic efficacy
    Study

    n = 33

    Comparator
    Dexamethasone with the same background antiemetics
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    2 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    No statistically significant difference was noted between the two drugs with regard to efficacy or side effects.
    2 context sentences
    Summary · context
    In order to compare the safety and the antiemetic effectiveness of tetracosactide (TCS) or beta 1,24 ACTH with those of dexamethasone (DXM) as an adjunct to high-dose metoclopramide, diphenhydramine and clorazepate, 33 patients receiving cisplatin based cancer chemotherapy were enrolled in a double-…
    Summary · context
    TCS and DXM were given intravenously, respectively at a dose of 2 mg and 20 mg, and concurrently to the cisplatin infusion.
  2. 02HumanNon-randomized trialSafety outcome

    In cisplatin chemotherapy patients, tetracosactide and dexamethasone with shared background antiemetics did not differ significantly in side effects.

    In plain wordsIn cisplatin chemotherapy patients, tetracosactide and dexamethasone with the same background drugs did not differ significantly in side effects.

    Peptide
    Cosyntropin
    Outcome
    No significant changeSide effects
    Study

    n = 33

    Comparator
    Dexamethasone with the same background antiemetics
    Outcome group
    Adverse events · Whole body
    Studied dose
    2 mg · intravenousAs given in this study (human).

    Source sentences

    Summary
    No statistically significant difference was noted between the two drugs with regard to efficacy or side effects.
    2 context sentences
    Summary · context
    In order to compare the safety and the antiemetic effectiveness of tetracosactide (TCS) or beta 1,24 ACTH with those of dexamethasone (DXM) as an adjunct to high-dose metoclopramide, diphenhydramine and clorazepate, 33 patients receiving cisplatin based cancer chemotherapy were enrolled in a double-…
    Summary · context
    TCS and DXM were given intravenously, respectively at a dose of 2 mg and 20 mg, and concurrently to the cisplatin infusion.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.